Chicago, USA - October 29, 2024: Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its participation in an upcoming webinar hosted by Lantern Pharma. The discussion will focus on the collaboration aimed at accelerating the development of Actuate's lead investigational drug, elraglusib, which targets difficult-to-treat cancers. The webinar is scheduled for October 30, 2024.
Fort Worth, Texas, USA - October 29, 2024: Sunrun has appointed John Trinta to its Board of Directors. This strategic move is expected to enhance the company's leadership as it navigates the evolving renewable energy sector.